Begin Phase 1 study of mRNA-1189 Epstein-Barr virus vaccine
Delivered after the deadline (10 days after the deadline)
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 25 Feb 2021
- Due
- 31 Dec 2021
- Delivered
- 10 Jan 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Moderna is planning to begin a Phase 1 study of mRNA-1189 in 2021”
What we found
Evidence strength A What the grades mean
The company's 8-K of January 10, 2022 reported the first participant dosed in the mRNA-1189 Phase 1 study, after the 2021 deadline.
-
A Moderna 8-K filed 2022-01-10
“The first participant has been dosed in the Phase 1 study of mRNA-1189.” ✓ confirmed on the page
-
A Moderna 10-K filed 2022-02-25
“We announced the dosing of the first participant in January 2022 and we expect to enroll approximately 270 participants.” ✓ confirmed on the page
Market reaction: the shares moved +3.2% against the S&P 500 over the three sessions around the disclosure (7 Jan 2022 to 12 Jan 2022). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Begin
- Deliverable
- Phase 1 study of mRNA-1189 EBV vaccine
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesGemini (Google) re-read the evidence blind and read it as “Not met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Moderna? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-MRNA-006161 · Corrections policy